Danaher (DHR) has ceased trying to acquire Catalent (CTLT) after expressing interest in purchasing the contract manufacturer, Bloombreg’s Michelle F. Davis and Liana Baker report, citing people familiar with the matter. Danaher, which is no longer considering making an offer, had made overtures to Catalent valuing the company at a significant premium, the authors note. Catalent shares are down 6.5% after the news. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DHR:
- Catalent (NYSE:CTLT) Is Not on Danaher’s (NYSE:DHR) Buy List
- Danaher Announces Conversion Date for Series B Mandatory Convertible Preferred Stock
- Danaher price target lowered to $270 from $290 at Barclays
- 5 Best Healthcare Stocks to Invest in Now, According to Analysts
- Citi puts ‘positive catalyst watches’ on three life science stocks